Stability of 111In-bleomycin in vivo--properties compared with 57Co-bleomycin.
111Indium-bleomycin (111In-BLM) and 57Co-bleomycin (57Co-BLM) were prepared and their distributions were compared in the tissues, blood, and urine in tumor-bearing and in untreated mice and rats. Autoradiographs of electrophoresis gels showed that patterns for urine from untreated and tumor-bearing animals, collected 1-3 h or 48 h after injection of 111In-BLM were similar to those for in vitro mixtures of urine and 111In-BLM, but differed from the patterns obtained with 111InCl3 under in vivo or in vitro conditions. In rats bearing mammary adenocarcinoma, 48 h after administration of the radiopharmaceutical, the activity ratio of tumor to eleven different tissues was 1.2-4.6 times higher for injected 111In-BLM than for 111InCl3 (P less than or equal to 0.001 or P less than or equal to 0.05). Imaging with a gamma camera depicted tumors in mice more distinctly with 111In-BLM than with 111InCl3. These findings were interpreted as reflecting the stability of 111In-BLM in vivo. The tumor concentration (%dose/g) was higher for the viable area than for the necrotic area for 111In-BLM, but the reverse was true for 57Co-BLM.
D000230:Adenocarcinoma / Q000000981:diagnostic imaging*; D000818:Animals; D001761:Bleomycin; D002855:Chromatography, Thin Layer; D003037:Cobalt Radioisotopes; D004341:Drug Evaluation; D004586:Electrophoresis; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging*; D007204:Indium; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging*; D051379:Mice; D008810:Mice, Inbred C57BL; D011868:Radioisotopes; D011877:Radionuclide Imaging; D051381:Rats; D011917:Rats, Inbred Lew; D014018:Tissue Distribution
D003037:Cobalt Radioisotopes; D011868:Radioisotopes; D007204:Indium; D001761:Bleomycin